13- 14% af patienterne behandlede med Rebif 44 mikrogram to gange ugentlig, vedvarende serumantistoffer mod interferon beta- 1a.
Clinical data suggest that after 24 to 48 months of treatment with Rebif 44 micrograms, approximately 13 to 14% of patients develop persistent serum antibodies to interferon beta-1a.